The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of at-101 (R-(-)-gossypol) in combination with paclitaxel (P) and carboplatin (C) in solid tumors including castrate-resistant prostate cancer (CRPC).
Yujie Zhao
No relevant relationships to disclose
Murugesan Gounder
No relevant relationships to disclose
Hongxia Lin
No relevant relationships to disclose
Kiomi Harris Addo
No relevant relationships to disclose
Kelly Taber Levinson
No relevant relationships to disclose
Marjorie LaRosiliere
No relevant relationships to disclose
Susan Goodin
No relevant relationships to disclose
Rebecca Anne Moss
No relevant relationships to disclose
Antoinette R. Tan
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose